Quisinostat HCl
| CAS No. | 1083078-98-1 | Cat. No. | BCP44306 |
| Name | Quisinostat HCl | ||
| Synonyms | Quisinostat hydrochloride;JNJ26481585; JNJ-26481585; JNJ 26481585; | ||
| Formula | C21H27ClN6O2 | M. Wt | 430.94 |
| Description | Quisinostat, also known as JNJ-26481585, is an orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor JNJ-26481585 inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation. | ||
| Pathways | Cell Cycle/DNA Damage Epigenetics | ||
| Targets | HDAC | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.